Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria

Infection and Immunity

Volumn 71, Issue 10, 2003, Pages 5803-5813

  Feezor, Robert J ^a   Oberholzer, Caroline ^a,b   Baker, Henry V ^a   Novick, Daniela ^c   Rubinstein, Menachem ^c   Moldawer, Lyle L ^a   Pribble, John ^d   Souza, Sonia ^d   Dinarello, Charles A ^e   Ertel, Wolfgang ^b   Oberholzer, Andreas ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROCALCITONIN; PROTEIN C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL FEATURE; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FEMALE; GENE CONTROL; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS AUREUS;

CYTOKINES; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION PROFILING; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; STAPHYLOCOCCUS AUREUS;

EID: 0141446081     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.10.5803-5813.2003     Document Type: Article

References (36)

1. Abraham, E. 1999. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. 25:556-566.
2. American College of Chest Physicians/Society of Critical Care Medicine. 1992. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20:864-874.
3. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
4. Baue, A. E. 1997. Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? Arch. Surg. 132:703-707.
5. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. LaRosa, J. F. Dhainaut, A. Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W. Ely, and C. J. Fisher, Jr. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709.
6. Bjork, L., J. Andersson, M. Ceska, and U. Andersson. 1992. Endotoxin and Staphylococcus aureus enterotoxin A induce different patterns of cytokines. Cytokine 4:513-519.
7. Bocker, U., T. Manigold, J. M. Watson, M. V. Singer, and S. Rossol. 2001. Regulation of Staphylococcus aureus-mediated activation of interleukin-18 in peripheral blood mononuclear cells. Eur. Cytokine Netw. 12:631-638.
8. Boldrick, J. C., A. A. Alizadeh, M. Diehn, S. Dudolt, C. L. Liu, C. E. Belcher, D. Botstein, L. M. Staudt, P. O. Brown, and D. A. Relman. 2002. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc. Natl. Acad. Sci. USA 99:972-977.
9. Bone, R. C. 1994. Gram-positive organisms and sepsis. Arch. Intern. Med. 154:26-34.
10. Centers for Disease Control and Prevention. 1990. Increase in National Hospital Discharge Survey rates for septicemia-United States. 1979-1987. Morb. Mortal. Wkly. Rep. 39:31-34.
11. Cockerill, F. R., III, J. G. Hughes, E. A. Vetter, R. A. Mueller, A. L. Weaver, D. M. Ilstrup, J. E. Rosenblatt, and W. R. Wilson. 1997. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. Clin. Infect. Dis. 24:403-418.
12. De Kimpe, S. J., M. Kengatharan, C. Thiemermann, and J. R. Vane. 1995. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl. Acad. Sci. USA 92:10359-10363.
13. Dinarello, C. A. 2001. Novel targets for interleukin 18 binding protein. Ann. Rheum. Dis. 60(Suppl. 3):iii18-iii24.
14. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863-14868.
15. Fong, Y. M., M. A. Marano, L. L. Moldawer, H. Wei, S. E. Calvano, J. S. Kenney, A. C. Allison, A. Cerami, G. T. Shires, and S. F. Lowry. 1990. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J. Clin. Invest. 85:1896-1904.
16. Fry, D. E. 2000. Sepsis syndrome. Am. Surg. 66:126-132.
17. Kaisho, T., K. Hoshino, T. Iwabe, O. Takeuchi, T. Yasui, and S. Aldra. 2002. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int. Immunol. 14:695-700.
18. Krishnagopalan, S., and R. P. Dellinger. 2001. Innovative therapies for sepsis. BioDrugs 15:645-654.
19. Muller-Alouf, H., J. E. Alouf, D. Gerlach, J. H. Ozegowski, C. Fitting, and J. M. Cavaillon. 1994. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infect. Immun. 62:4915-4921.
20. Nau, G. J., J. F. Richmond, A. Schlesinger, E. G. Jennings, E. S. Lander, and R. A. Young. 2002. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 99:1503-1508.
21. Novick, D., S. H. Kim, G. Fantuzzi, L. L. Reznikov, C. A. Dinarello, and M. Rubinstein. 1999. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127-136.
22. Novick, D., B. Schwartsburd, R. Pinkus, D. Suissa, I. Belzer, Z. Sthoeger, W. F. Keane, Y. Chvatchko, S. H. Kim, G. Fantuzzi, C. A. Dinarello, and M. Rubinstein. 2001. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14:334-342.
23. Oberholzer, A., C. Oberholzer, R. M. Minter, and L. L. Moldawer. 2001. Considering immunomodulatory therapies in the septic patient: should apoptosis be a potential therapeutic target? Immunol. Lett. 75:221-224.
24. Oberholzer, A., U. Steckholzer, M. Kurimoto, O. Trentz, and W. Ertel. 2001. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock 16:411-414.
25. Opal, S. M., and J. Cohen. 1999. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit. Care Med. 27:1608-1616.
26. Parrillo, J. E. 1993. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328:1471-1477.
27. Parrillo, J. E., M. M. Parker, C. Natanson, A. F. Sulfredini, R. L. Danner, R. E. Cunnion, and F. P. Ognibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113:227-242.
28. Takeuchi, O., and S. Akira. 2001. Toll-like receptors; their physiological role and signal transduction system. Int. Immunopharmacol. 1:625-635.
29. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451.
30. Tannahill, C. L., K. Fukuzuka, T. Marum, Z. Abouhamze, S. L. MacKay, E. M. Copeland III, and L. L. Moldawer. 1999. Discordant tumor necrosis factor-alpha superfamily gene expression in bacterial peritonitis and endotoxemic shock. Surgery 126:349-357.
31. Valles, J., C. Leon, F. Alvarez-Lerma, et al. 1997. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Clin. Infect. Dis. 24:387-395.
32. Vincent, J. L. 1998. Search for effective immunomodulating strategies against sepsis. Lancet 351:922-923.
33. Wang, J. E., P. F. Jorgensen, M. Almlof, C. Thiemermann, S. J. Foster, A. O. Aasen, and R. Solberg. 2000. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect. Immun. 68:3965-3970.
34. Wang, Z. M., C. Liu, and R. Dziarski. 2000. Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J. Biol. Chem. 275:20260-20267.
35. Wheeler, A. P., and G. R. Bernard. 1999. Treating patients with severe sepsis. N. Engl. J. Med. 340:207-214.
36. Zeni, F., B. Freeman, and C. Natanson. 1997. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25:1095-1100.